Companies & Industry
GSK commits $800 million to a Pennsylvania biologics hub as pharma manufacturing moves closer to U.S. health systems
The Upper Merion site will combine commercial biologics production, a pilot plant and quality labs, part of GSK's $30 billion U.S. pledge through 2030. Construction starts in 2027, so supply effects are years out.
Oct 14, 2026
